Tucatinib in combination with trastuzumab and capecitabine yielded significant intracranial responses in patients with previously treated HER2-positive metastatic breast cancer and brain metastases.
Lisa Astor
Advertisement
Articles by Lisa Astor
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Radiotherapy Dose Escalation Did Not Improve Efficacy/QOL in Anal Cancer
2
Nogapendekin Alfa Combo Earns Approval in Saudi Arabia for Metastatic NSCLC
3
Gemogenovatucel-T Exhibits Survival Benefit in Epithelial Ovarian Cancer
4
Taiwan FDA Approves Nivolumab/Ipilimumab for MSI-H/dMMR Metastatic CRC
5